Fig. 9From: Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine modelRECIST criteria applied to the therapeutic assay of liposomes. B16OVA tumor bearing mice intravenously administered with three cycles (cycle/every 72 h) of different treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously administered at 3 mg/kg and tumor progression was measured twice per week. The values, expressed as percentage, were calculated comparing the tumor size at a specific time point with its initial size at day 7 after cell inoculationBack to article page